Rate My Professor Fabien Delerue

Fabien Delerue is an Honorary Senior Research Fellow and Head of the Genome Editing at Macquarie (GEM), a transgenic core facility that is part of the Dementia Research Centre within Macquarie Medical School at Macquarie University. He holds a Master of Science degree from the University of Bordeaux in France and a Doctor of Philosophy from the University of Sydney, completed in 2013. Delerue began his research career at the preclinical Central Nervous System Centre of Hoffmann-La Roche Ltd in Basel, Switzerland, where he gained expertise in in vivo activities, particularly animal models of diseases. In 2013, he moved to the University of New South Wales, becoming a Lecturer and managing the Transgenic Animal Unit. In 2018, he joined Macquarie University as Senior Lecturer to head the GEM transgenic facility, a role he continues to hold alongside his current honorary position.

Dr. Delerue's research focuses on developing new genome editing and gene transfer techniques, with particular applications to dementia and rare genetic disorders such as FoxG1 syndrome. His interests encompass the optimization of gene transfer methods for generating genetically modified animals, development of assisted reproductive techniques, discovery and engineering of new endonucleases, and investigation of pathomechanisms in genetic disorders. His contributions to transgenesis and genome editing are internationally recognized, supported by a career spanning over 20 years in assisted reproduction and animal model generation for diseases. Key publications include "PLP1-targeting antisense oligonucleotides improve FOXG1 syndrome mice" (Tan et al., 2024, International Journal of Molecular Sciences), "Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice" (Ke et al., 2024, Neuron), "Artificial intelligence-driven meta-analysis of brain gene expression identifies novel gene candidates and a role for mitochondria in Alzheimer's disease" (Finney et al., 2023, Computational and Structural Biotechnology Journal), "Blood-based transcriptomic biomarkers are predictive of neurodegeneration rather than Alzheimer’s disease" (Shvetcov et al., 2023, International Journal of Molecular Sciences), and "The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury" (Shvetcov et al., 2023, Neuroscience and Biobehavioral Reviews). His work has garnered over 4,200 citations and an h-index of 17.